Clinical Trials Browser

Brentuximab Vedotin × Thoracic × 30 days × Clear all

NCT03007030 2026-05-15

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

Phase 2 Recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant